Digestive Disease Week (DDW) 2023

Chicago, IL, US 06 May 2023 - 09 May 2023

Subgroup analysis CONFIRMs telipressin potential for treating HRS, alcoholic hepatitis

30 May 2023 by

In individuals with hepatorenal syndrome (HRS) compounded by alcoholic hepatitis (AH), treatment with the synthetic, long-acting vasopressin analogue terlipressin led to the achievement of verified HRS reversal, a subgroup analysis of the phase III CONFIRM trial has shown.

Subgroup analysis CONFIRMs telipressin potential for treating HRS, alcoholic hepatitis

30 May 2023

New data fortify obeticholic acid role in NASH treatment

29 May 2023 by

In the new analysis of the REGENERATE trial, the FXR* agonist obeticholic acid (OCA) was generally well tolerated and demonstrated a favourable safety profile in patients with nonalcoholic steatohepatitis (NASH).

New data fortify obeticholic acid role in NASH treatment

29 May 2023

Vedolizumab prevents postop CD recurrence: new indication likely

24 May 2023 by

Patients with resected Crohn’s disease (CD) who were treated with the gut-selective α4β7-integrin inhibitor vedolizumab were less likely to have endoscopic signs of recurrence compared with placebo in the Reprevio study presented at DDW 2023.

Vedolizumab prevents postop CD recurrence: new indication likely

24 May 2023

Fexuprazan brings relief in erosive esophagitis, noninferior to esomeprazole

23 May 2023 by

The novel potassium-competitive acid blocker fexuprazan shows comparable safety and efficacy to the proton pump inhibitor esomeprazole in the treatment of Chinese patients with erosive esophagitis, as shown in the results of a phase III study presented at DDW 2023.

Fexuprazan brings relief in erosive esophagitis, noninferior to esomeprazole

23 May 2023

LIBERTY-UC: Maintenance subcutaneous infliximab eases moderate-to-severe UC

22 May 2023 by

The subcutaneous infliximab formulation CT-P13 appears beneficial in the maintenance treatment of patients with moderately to severely active ulcerative colitis (UC), with data from the phase III study LIBERTY-UC showing that the drug outperforms placebo in multiple endpoints.

LIBERTY-UC: Maintenance subcutaneous infliximab eases moderate-to-severe UC

22 May 2023

Is long-term ustekinumab safe and effective in children with Crohn’s disease?

22 May 2023 by

Use of ustekinumab for up to 4 years in paediatric patients with Crohn’s disease (CD) shows similar efficacy, safety, pharmacokinetics (PK), and immunogenicity to that seen in adult patients, according to the results of the UniStar study long-term extension.

Is long-term ustekinumab safe and effective in children with Crohn’s disease?

22 May 2023

Digital gut-directed hypnotherapy reduces abdominal pain in IBS patients

20 May 2023 by

Digital gut-directed hypnotherapy (GDH) programme reduces abdominal pain in adults with irritable bowel syndrome (IBS) compared with digital muscle relaxation (MR), according to a study presented at DDW 2023.

Digital gut-directed hypnotherapy reduces abdominal pain in IBS patients

20 May 2023

Smoking, asthma tied to worse faecal incontinence symptoms

19 May 2023 by

More severe faecal incontinence symptoms appear to burden tobacco smokers, reveals a recent study presented at DDW 2023. Tobacco use is also associated with weaker anal sphincter tone and increased rectal hypersensitivity on high-resolution anorectal manometry (HRAM).

Smoking, asthma tied to worse faecal incontinence symptoms

19 May 2023

Guselkumab safe, effective as induction therapy for UC

17 May 2023 by

Induction therapy with guselkumab, an interleukin-23 p19 subunit antagonist, results in clinical and symptomatic remission, as well as other endoscopic improvements in patients with moderate-to-severe active ulcerative colitis (UC), according to the QUASAR study presented at DDW 2023.

Guselkumab safe, effective as induction therapy for UC

17 May 2023